Table. 1.

Patient demographics

Variable Living donor (n=225) Deceased donor (n=75) P-value
Sex
Recipient 0.015
Male 142 (63.1) 35 (46.7)
Female 83 (36.9) 40 (53.3)
Donor 0.005
Male 100 (44.4) 48 (64.0)
Female 125 (55.6) 27 (36.0)
Age (yr)
Recipient 46.4±13.2 51.7±11.3 0.002
Donor 42.4±11.8 46.7±13.6 0.008
Etiology 0.097
DM 58 (25.8) 20 (26.7)
GN 51 (22.7) 22 (29.3)
IgA 40 (17.8) 0 (0.0)
HTN 23 (10.2) 6 (8.0)
ADPKD 10 (4.4) 5 (6.7)
FSGS 8 (3.6) 2 (2.7)
Reflux 4 (1.8) 1 (1.3)
Othersa) 9 (4.0) 3 (4.0)
Unknown 22 (9.8) 17 (22.7)
Pretransplant renal replacement <0.001
Hemodialysis 131 (58.2) 51 (68.0)
Peritoneal dialysis 13 (5.8) 19 (25.8)
No dialysis 81 (36.0) 5 (6.7)
Mean duration (mo) 7.87 84.14 <0.001
Donor-recipient relation
Living, related 151 (67.1)
Sibling 64 (42.4)
Offspring 50 (33.1)
Parent 28 (18.5)
Others 9 (6.0)
Living, unrelated 74 (32.9)
Spouse 71 (95.9)
Others 3 (4.1)
ABO compatibility <0.001
ABO-compatible 183 (81.3) 75 (100.0)
ABO-incompatible 42 (18.7) 0 (0.0)
HLA mismatch 0.022
0 22 (9.8) 10 (13.3)
1 15 (6.7) 1 (1.3)
2 32 (14.2) 5 (6.7)
3 70 (31.1) 21 (28.0)
4 28 (12.4) 21 (28.0)
5 39 (17.3) 13 (17.3)
6 18 (8.0) 4 (5.3)
Immunosuppression <0.001
Induction agent
No 50 (22.2) 5 (6.7)
Simulect 171 (76.0) 64 (85.3)
ATG 4 (1.8) 6 (8.0)
Maintenance agent
Calcineurin inhibitor <0.001
Tacrolimus 177 (78.7) 73 (97.3)
Cyclosporin A 48 (21.3) 2 (2.7)
Antimetabolite 0.898
Mycophenolate mofetil 185 (82.2) 61 (81.3)
Mycophenolic acid 40 (17.8) 14 (18.7)
Prednisolone 225 (100.0) 75 (100.0) -
Desensitization for ABOi-KT recipient 42 (100.0)
Rituximab 42 (100.0)
Plasmapheresis 38 (90.5)
Initial anti-A/B titersb)
IgG 1:16 (1:2–1:256)
IgM 1:8 (1:1–1:128)
Preoperative anti-A/B titerb)
IgG 1:4 (negative-1:16)
IgM 1:1 (negative-1:4)

Values are presented as number (%) or mean±standard deviation.

DM, diabetes mellitus; GN, glumerulonephritis; Ig, immunoglobulin; HTN, hypertension; ADPKD, autosomal dominant polycystic kidney disease; FSGS, focal segmental glumerulosclerosis; HLA, human leukocyte antigen; ATG, anti-thymocyte globulin; ABOi-KT, ABO-incompatible kidney transplantation.

a)Others include Wilms’ tumor (1 case), lupus nephritis (3 cases), Alport syndrome (2 cases), drug toxicity (1 case), renal agenesis (1 case), Henoch-Schonlein nephritis (1 case), Hantaan virus infection (1 case), and acute kidney injury (1 case); b)Median (range).

Korean J Transplant 2020;34:154~166 https://doi.org/10.4285/kjt.2020.34.3.154